The full data from the remdesivir trial by the National Institutes of Health (NIH) has finally been released, weeks after preliminary results were shared via press release. Those early results generated a great deal of hype and a world wide stampede for the drug. But the release of the full data tells a different story.

The conclusion of the NIH study, published in The New England Journal of Medicine, states: 

“These preliminary findings support the use of remdesivir for patients who are hospitalized with Covid-19 and require supplemental oxygen therapy. However, given high mortality despite the use of remdesivir, it is clear that treatment with an antiviral drug alone is not likely to be sufficient. Future strategies should evaluate antiviral agents in combination with other therapeutic approaches or combinations of antiviral agents to continue to improve patient outcomes in Covid-19.”

There are a few problems this paragraph highlights.

Read full article on Forbes

Originally posted on Forbes (May 26, 2020)